BCL2L1 and cancer: Since cancer cells may bypass the inhibition of one target, e.g. a reduction in BCL2 protein content can be compensated by the induction of Bcl-xL (24), the combined knockdown of antiapoptotic genes may be more suitable for BCa therapy.